Novartis AG (TSX:NVS)

Market Cap	402.55B +42.5%
Revenue (ttm)	77.71B +9.6%
Net Income	19.17B +17.1%
EPS	9.80 +21.8%
Shares Out	n/a
PE Ratio	21.00
Forward PE	17.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	604
Average Volume	1,570
Open	28.53
Previous Close	28.45
Day's Range	28.53 - 28.55
52-Week Range	20.11 - 28.55
Beta	n/a
RSI	66.22
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland, the United States, China, Germany, and internationally. It focuses on developing products in cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and other therapeutic areas. The company offers Entresto, an angiotensin receptor-neprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, a...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: NVS

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Financial numbers in USD